AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society. We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.
The state-of-the-art AstraZeneca R&D Boston facility, located in Waltham, Massachusetts, reflects the innovative culture of AstraZeneca’s leading-edge pharmaceutical research. Innovative medicine teams focused on infection and oncology conduct research from discovery to Clinical Proof of Concept (PoC-Phase II success). They are joined by scientists trained in safety assessment, pharmaceutical development, R&D Information, predictive science, and personalised healthcare who work collaboratively to help bring to market medicines that deliver value to patients, payers, and prescribers. In addition to these core therapy areas, the site is home to scientists working to identify new opportunities for patient health outside of our existing research areas and professionals involved in business development.
In 2012 AstraZeneca opened its Neuroscience offices in Kendall Square, Cambridge, to pursue a new virtual early discovery/development R&D model that fully relies on collaborations with external partners.
AstraZeneca is also pleased to have a global operations and field-based commercial employees located in Massachusetts.
Nov 19, 2019
Posted by AstraZeneca Pharmaceuticals LP